APA (7th ed.) Citation

He, C., Mi, X., Xu, G., Xu, X., Xin, W., Zhong, L., . . . Ding, H. (2024). Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. PLoS ONE, 19(5), 1. https://doi.org/10.1371/journal.pone.0302961

Chicago Style (17th ed.) Citation

He, Chaoneng, et al. "Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma in China." PLoS ONE 19, no. 5 (2024): 1. https://doi.org/10.1371/journal.pone.0302961.

MLA (9th ed.) Citation

He, Chaoneng, et al. "Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma in China." PLoS ONE, vol. 19, no. 5, 2024, p. 1, https://doi.org/10.1371/journal.pone.0302961.